[{"id":"757c7ea9-28ea-4973-bbc9-a09748839d13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039801","created_at":"2021-09-10T16:57:15.373Z","updated_at":"2025-02-25T15:35:16.395Z","phase":"Phase 1","brief_title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05039801","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2","pipe":" | ","alterations":" PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Truqap (capivasertib) • IPN60090"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-10"},{"id":"d8999917-3c0d-4b22-aa4a-6a2e1a2de773","acronym":"TRITON","url":"https://clinicaltrials.gov/study/NCT06008093","created_at":"2023-08-23T15:11:10.888Z","updated_at":"2025-02-25T16:55:15.589Z","phase":"Phase 3","brief_title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT06008093 - TRITON","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • KRAS • ALK • STK11 • KEAP1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation","tags":["EGFR • KRAS • ALK • STK11 • KEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 04/04/2024","start_date":" 04/04/2024","primary_txt":" Primary completion: 08/17/2027","primary_completion_date":" 08/17/2027","study_txt":" Completion: 03/20/2031","study_completion_date":" 03/20/2031","last_update_posted":"2025-02-04"},{"id":"89c99f17-c261-4cdb-a20c-29d1474aae9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06775158","created_at":"2025-02-25T20:23:58.570Z","updated_at":"2025-02-25T20:23:58.570Z","phase":"","brief_title":"Perioperative Myocardial and Renal Injury in Patients Undergoing Hepatic Resection","source_id_and_acronym":"NCT06775158","lead_sponsor":"Istanbul Saglik Bilimleri University","biomarkers":" KEAP1","pipe":"","alterations":" ","tags":["KEAP1"],"overall_status":"Completed","enrollment":" Enrollment 128","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 06/20/2024","primary_completion_date":" 06/20/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2025-01-14"},{"id":"92435528-4415-4d93-8e63-2a53a10bdf30","acronym":"","url":"https://clinicaltrials.gov/study/NCT04250545","created_at":"2021-01-18T20:39:21.304Z","updated_at":"2024-07-02T16:34:58.880Z","phase":"Phase 1","brief_title":"Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04250545","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • ALK • ROS1 • KEAP1 • NFE2L2","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation","tags":["KRAS • BRAF • ALK • ROS1 • KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228) • telaglenastat (CB-839)"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"7315975a-48e7-478f-a922-63b5c722e7c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03872427","created_at":"2021-01-18T19:05:39.832Z","updated_at":"2024-07-02T16:35:03.365Z","phase":"Phase 2","brief_title":"Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study","source_id_and_acronym":"NCT03872427","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" STK11 • NF1 • KEAP1 • NFE2L2","pipe":" | ","alterations":" STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["STK11 • NF1 • KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 12/14/2019","start_date":" 12/14/2019","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-05-16"},{"id":"ccc9d7e0-e22a-44d5-935f-fcc41002f6d6","acronym":"OPTIM","url":"https://clinicaltrials.gov/study/NCT03253289","created_at":"2021-01-18T16:04:17.972Z","updated_at":"2024-07-02T16:35:14.197Z","phase":"Phase 1","brief_title":"Meclizine for Hepatocellular Carcinoma","source_id_and_acronym":"NCT03253289 - OPTIM","lead_sponsor":"Tannaz Armaghnay","biomarkers":" MYC • KEAP1","pipe":"","alterations":" ","tags":["MYC • KEAP1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 10/13/2017","start_date":" 10/13/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-03-18"},{"id":"64165b3f-b55d-41f6-83d8-fad55beb1590","acronym":"","url":"https://clinicaltrials.gov/study/NCT05275868","created_at":"2022-03-11T14:53:23.220Z","updated_at":"2024-07-02T16:35:17.689Z","phase":"Phase 1","brief_title":"Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05275868","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KEAP1 • NFE2L2","pipe":" | ","alterations":" KEAP1 mutation • NFE2L2 mutation","tags":["KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGY825"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 10/05/2022","start_date":" 10/05/2022","primary_txt":" Primary completion: 08/17/2026","primary_completion_date":" 08/17/2026","study_txt":" Completion: 08/17/2026","study_completion_date":" 08/17/2026","last_update_posted":"2024-02-26"},{"id":"425958b5-9602-4c65-963a-dd2cc9188c33","acronym":"","url":"https://clinicaltrials.gov/study/NCT04638478","created_at":"2021-01-19T20:38:09.392Z","updated_at":"2024-07-02T16:35:29.624Z","phase":"","brief_title":"PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI","source_id_and_acronym":"NCT04638478","lead_sponsor":"Maastricht Radiation Oncology","biomarkers":" KEAP1","pipe":"","alterations":" ","tags":["KEAP1"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 04/08/2025","primary_completion_date":" 04/08/2025","study_txt":" Completion: 04/08/2025","study_completion_date":" 04/08/2025","last_update_posted":"2023-11-10"},{"id":"0b078c31-b834-443b-9dbb-957a373918c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04190433","created_at":"2023-03-10T18:01:33.701Z","updated_at":"2024-07-02T16:35:47.261Z","phase":"Phase 2","brief_title":"Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial","source_id_and_acronym":"NCT04190433","lead_sponsor":"Mayo Clinic","biomarkers":" KEAP1","pipe":"","alterations":" ","tags":["KEAP1"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 04/18/2023","primary_completion_date":" 04/18/2023","study_txt":" Completion: 04/18/2023","study_completion_date":" 04/18/2023","last_update_posted":"2023-05-24"},{"id":"4b7d48bf-777b-4cc6-8d23-6e3db810e6e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05768321","created_at":"2023-03-14T14:01:49.188Z","updated_at":"2024-07-02T16:35:53.169Z","phase":"Phase 1","brief_title":"Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation","source_id_and_acronym":"NCT05768321","lead_sponsor":"GenEros Biopharma Hangzhou Ltd","biomarkers":" KRAS • STK11 • KEAP1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS • STK11 • KEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GEC-255"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 05/30/2024","study_completion_date":" 05/30/2024","last_update_posted":"2023-03-16"},{"id":"42fec90d-1616-4bcb-ba10-1468cd201d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05568212","created_at":"2022-10-05T12:56:03.628Z","updated_at":"2024-07-02T16:36:02.981Z","phase":"Phase 2","brief_title":"Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab","source_id_and_acronym":"NCT05568212","lead_sponsor":"Fondazione Ricerca Traslazionale","biomarkers":" TP53 • TMB • BRCA1 • STK11 • KEAP1 • ERCC1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • TP53 expression","tags":["TP53 • TMB • BRCA1 • STK11 • KEAP1 • ERCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 05/02/2022","start_date":" 05/02/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-10-05"},{"id":"49802c3e-ce1e-4e25-99ea-df4984c5d29c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05276726","created_at":"2022-03-11T14:53:34.119Z","updated_at":"2024-07-02T16:36:03.348Z","phase":"Phase 1/2","brief_title":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","source_id_and_acronym":"NCT05276726","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS • STK11 • KEAP1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12","tags":["KRAS • STK11 • KEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Airuikai (glecirasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2022-09-28"},{"id":"44c79ae3-87c7-4448-91b8-627842e7c950","acronym":"SELINA","url":"https://clinicaltrials.gov/study/NCT05534906","created_at":"2022-09-10T12:57:59.878Z","updated_at":"2024-07-02T16:36:04.112Z","phase":"","brief_title":"The Detection of Small Early Liver Cancer With Natural History Follow up","source_id_and_acronym":"NCT05534906 - SELINA","lead_sponsor":"University of Oxford","biomarkers":" KEAP1","pipe":"","alterations":" ","tags":["KEAP1"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 05/23/2022","start_date":" 05/23/2022","primary_txt":" Primary completion: 06/01/2035","primary_completion_date":" 06/01/2035","study_txt":" Completion: 06/01/2035","study_completion_date":" 06/01/2035","last_update_posted":"2022-09-12"},{"id":"73bd1f58-90ec-4a1d-b5ea-f69e2113837d","acronym":"CASUS-WP4","url":"https://clinicaltrials.gov/study/NCT04530201","created_at":"2021-01-18T21:41:24.815Z","updated_at":"2024-07-02T16:36:08.858Z","phase":"","brief_title":"CASUS: Validation for Detection of Precursor Lesions","source_id_and_acronym":"NCT04530201 - CASUS-WP4","lead_sponsor":"Universiteit Antwerpen","biomarkers":" KEAP1 • GAPDH","pipe":"","alterations":" ","tags":["KEAP1 • GAPDH"],"overall_status":"Completed","enrollment":" Enrollment 332","initiation":"Initiation: 08/20/2020","start_date":" 08/20/2020","primary_txt":" Primary completion: 10/20/2021","primary_completion_date":" 10/20/2021","study_txt":" Completion: 02/28/2022","study_completion_date":" 02/28/2022","last_update_posted":"2022-06-15"},{"id":"8ae6d248-ecbb-408f-8f2f-48c143b00eec","acronym":"","url":"https://clinicaltrials.gov/study/NCT02417701","created_at":"2021-01-17T17:54:54.823Z","updated_at":"2024-07-02T16:36:13.984Z","phase":"Phase 2","brief_title":"Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer","source_id_and_acronym":"NCT02417701","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • KEAP1 • NFE2L2 • CD4","pipe":" | ","alterations":" KRAS mutation • KEAP1 mutation • NFE2L2 mutation","tags":["KRAS • KEAP1 • NFE2L2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 10/06/2016","start_date":" 10/06/2016","primary_txt":" Primary completion: 12/28/2020","primary_completion_date":" 12/28/2020","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2022-04-05"},{"id":"428f1c7d-3c9d-4ad6-9649-3c2232730cb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01211483","created_at":"2021-06-17T00:52:36.913Z","updated_at":"2024-07-02T16:36:29.003Z","phase":"Phase 1b/2","brief_title":"Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01211483","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" KEAP1 • NRG1","pipe":"","alterations":" ","tags":["KEAP1 • NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • patritumab (U3-1287)"],"overall_status":"Completed","enrollment":" Enrollment 222","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 11/23/2013","study_completion_date":" 11/23/2013","last_update_posted":"2021-06-16"},{"id":"663bb1f3-2e37-4746-adc4-406a2c0b05de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04823793","created_at":"2021-04-01T17:52:21.761Z","updated_at":"2024-07-02T16:36:32.268Z","phase":"","brief_title":"Fecal DNA Methylation Test for Colorectal Cancer Screening","source_id_and_acronym":"NCT04823793","lead_sponsor":"Tri-Service General Hospital","biomarkers":" KEAP1 • GAPDH","pipe":"","alterations":" ","tags":["KEAP1 • GAPDH"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/31/2021","start_date":" 03/31/2021","primary_txt":" Primary completion: 03/20/2023","primary_completion_date":" 03/20/2023","study_txt":" Completion: 03/20/2023","study_completion_date":" 03/20/2023","last_update_posted":"2021-04-07"},{"id":"729a22f0-85f6-443f-b419-1d2b38ec152f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04264676","created_at":"2021-01-18T20:43:33.105Z","updated_at":"2024-07-02T16:36:38.191Z","phase":"Phase 2","brief_title":"Study of Oral Metronidazole on Postoperative Chemotherapy in Colorectal Cancer","source_id_and_acronym":"NCT04264676","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" KEAP1","pipe":"","alterations":" ","tags":["KEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 294","initiation":"Initiation: 03/31/2020","start_date":" 03/31/2020","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2020-11-25"},{"id":"2d1fef42-d797-428a-8f56-db28088ee549","acronym":"ECOG-ACRIN LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT04267913","created_at":"2021-01-18T20:44:15.415Z","updated_at":"2024-07-02T16:36:38.345Z","phase":"Phase 2","brief_title":"Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT04267913 - ECOG-ACRIN LUNG-MAP Sub-Study","lead_sponsor":"Southwest Oncology Group","biomarkers":" KEAP1 • NFE2L2 • CD4","pipe":" | ","alterations":" KEAP1 mutation • NFE2L2 mutation","tags":["KEAP1 • NFE2L2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Cyramza (ramucirumab) • sapanisertib (CB-228) • dexamethasone injection • lexatumumab (ETR2-ST01)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/05/2020","start_date":" 09/05/2020","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2020-11-20"},{"id":"03d625dd-d611-4c86-9919-6e7dfb83dd1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01558349","created_at":"2021-01-18T06:36:00.834Z","updated_at":"2024-07-02T16:36:56.176Z","phase":"","brief_title":"Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques","source_id_and_acronym":"NCT01558349","lead_sponsor":"Centre Hospitalier Universitaire de Nīmes","biomarkers":" KEAP1","pipe":"","alterations":" ","tags":["KEAP1"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 06/27/2013","start_date":" 06/27/2013","primary_txt":" Primary completion: 06/27/2017","primary_completion_date":" 06/27/2017","study_txt":" Completion: 06/27/2017","study_completion_date":" 06/27/2017","last_update_posted":"2019-08-28"},{"id":"050e1594-5ae9-448a-acc0-9a8eb9466d8c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03885076","created_at":"2022-06-23T18:55:31.253Z","updated_at":"2024-07-02T16:36:58.444Z","phase":"","brief_title":"Gamma Delta T Cells in AML","source_id_and_acronym":"NCT03885076","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" KEAP1","pipe":"","alterations":" ","tags":["KEAP1"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 08/23/2018","start_date":" 08/23/2018","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2019-07-02"},{"id":"426b20b4-7c14-4523-9184-8d93bb5edeb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02294578","created_at":"2021-01-18T10:49:07.477Z","updated_at":"2024-07-02T16:37:11.542Z","phase":"","brief_title":"Salivary Biomarkers for Non-small Cell Lung Cancer Detection","source_id_and_acronym":"NCT02294578","lead_sponsor":"PeriRx","biomarkers":" BRAF • KEAP1 • FGF19 • FRS2 • LZTS1 • CCN1","pipe":"","alterations":" ","tags":["BRAF • KEAP1 • FGF19 • FRS2 • LZTS1 • CCN1"],"overall_status":"Unknown status","enrollment":" Enrollment 166","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2018-04-12"},{"id":"d0720c37-2a12-40d4-ad50-cde72e0d168e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03259152","created_at":"2021-01-18T16:06:04.187Z","updated_at":"2024-07-02T16:37:18.509Z","phase":"Phase 3","brief_title":"Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone","source_id_and_acronym":"NCT03259152","lead_sponsor":"Hebei Medical University Third Hospital","biomarkers":" KEAP1 • COL1A1 • GAPDH • ACAN • TNFRSF11B","pipe":"","alterations":" ","tags":["KEAP1 • COL1A1 • GAPDH • ACAN • TNFRSF11B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2017-08-24"}]